Literature DB >> 11861823

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Claudine Serradeil-Le Gal1, Jean Wagnon, Jacques Simiand, Guy Griebel, Colette Lacour, Gilles Guillon, Claude Barberis, Gabrielle Brossard, Philippe Soubrié, Dino Nisato, Marc Pascal, Rebecca Pruss, Bernard Scatton, Jean-Pierre Maffrand, Gérard Le Fur.   

Abstract

(2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), the first selective, nonpeptide vasopressin V1b receptor antagonist yet described, has been characterized in vitro and in vivo. SSR149415 showed competitive nanomolar affinity for animal and human V1b receptors and exhibited much lower affinity for rat and human V1a, V2, and oxytocin receptors. Moreover, this compound did not interact with a large number of other receptors, enzymes, or ion channels. In vitro, SSR149415 behaved as a full antagonist and potently inhibited arginine vasopressin (AVP)-induced Ca2+ increase in Chinese hamster ovary cells expressing rat or human V1b receptors. The in vivo activity of SSR149415 has been studied in several models of elevated corticotropin secretion in conscious rats. SSR149415 inhibited exogenous AVP-induced increase in plasma corticotropin, from 3 mg/kg i.p. and 10 mg/kg p.o. upwards. Similarly, this compound antagonized AVP-potentiated corticotropin release provoked by exogenous corticoliberin at 3 mg/kg p.o. The effect lasted for more than 4 h at 10 mg/kg p.o. showing a long-lasting oral effect. SSR149415 (10 mg/kg p.o.) also blocked corticotropin secretion induced by endogenous AVP increase subsequent to body water loss. Moreover, 10 mg/kg i.p SSR149415 inhibited plasma corticotropin elevation after restraint-stress in rats by 50%. In the four-plate test, a mouse model of anxiety, SSR149415 (3 mg/kg p.o. upwards) displayed anxiolytic-like activity after acute and 7-day repeated administrations. Thus, SSR149415 is a potent, selective, and orally active V1b receptor antagonist. It represents a unique tool for exploring the functional role of V1b receptors and deserves to be clinically investigated in the field of stress and anxiety.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861823     DOI: 10.1124/jpet.300.3.1122

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  42 in total

Review 1.  Vasopressin and alcohol: a multifaceted relationship.

Authors:  Kathryn M Harper; Darin J Knapp; Hugh E Criswell; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2018-11-03       Impact factor: 4.530

Review 2.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

3.  Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.

Authors:  Cristiana Griffante; Andrew Green; Ornella Curcuruto; Carl P Haslam; Bryony A Dickinson; Roberto Arban
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

4.  The Vasopressin 1b Receptor Antagonist A-988315 Blocks Stress Effects on the Retrieval of Object-Recognition Memory.

Authors:  Areg Barsegyan; Piray Atsak; Wilfried B Hornberger; Peer B Jacobson; Marcel M van Gaalen; Benno Roozendaal
Journal:  Neuropsychopharmacology       Date:  2015-02-11       Impact factor: 7.853

5.  Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.

Authors:  M Iijima; T Yoshimizu; T Shimazaki; K Tokugawa; K Fukumoto; S Kurosu; T Kuwada; Y Sekiguchi; S Chaki
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

6.  Persistent increase in hypothalamic arginine vasopressin gene expression during protracted withdrawal from chronic escalating-dose cocaine in rodents.

Authors:  Yan Zhou; Yoav Litvin; Anna Paola Piras; Donald W Pfaff; Mary Jeanne Kreek
Journal:  Neuropsychopharmacology       Date:  2011-06-15       Impact factor: 7.853

7.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.

Authors:  M E Breuer; M M van Gaalen; W Wernet; S E F Claessens; R S Oosting; B Behl; S M Korte; H Schoemaker; G Gross; B Olivier; L Groenink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-31       Impact factor: 3.000

9.  Attenuated stress response to acute restraint and forced swimming stress in arginine vasopressin 1b receptor subtype (Avpr1b) receptor knockout mice and wild-type mice treated with a novel Avpr1b receptor antagonist.

Authors:  J A Roper; M Craighead; A-M O'Carroll; S J Lolait
Journal:  J Neuroendocrinol       Date:  2010-11       Impact factor: 3.627

Review 10.  Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.

Authors:  B Mouillac; M Manning; T Durroux
Journal:  Mini Rev Med Chem       Date:  2008-09       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.